טוען...
Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis
Objective: To determine the safety/tolerability and efficacy of anakinra in patients with SLE with leading joint involvement. Methods: In patients with SLE with active polyarthritis and no other uncontrolled systemic/organ manifestations, 100 mg/day anakinra was self administered subcutaneously for...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2005
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1755442/ https://ncbi.nlm.nih.gov/pubmed/15345502 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2004.025858 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|